TREATMENT OF STAGE III NSCLC AND MITIGATION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH THE TREATMENT

TREATMENT OF STAGE III NSCLC AND MITIGATION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH THE TREATMENT

This disclosure relates generally to dosage regimens for targeted TGF-β inhibition with a bi-functional fusion protein for use in a method of treating a treatment naïve patient diagnosed with stage III non-small cell lung cancer (NSCLC), and/or mitigating a pathological condition associated with che...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GRENGA, Italia, EL BAWAB, Samer, DUSSAULT, Isabelle, KHANDELWAL, Akash, CHRISTENSEN, Olaf, LAN, Yan, VUGMEYSTER, Yulia
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This disclosure relates generally to dosage regimens for targeted TGF-β inhibition with a bi-functional fusion protein for use in a method of treating a treatment naïve patient diagnosed with stage III non-small cell lung cancer (NSCLC), and/or mitigating a pathological condition associated with chemotherapy and radiotherapy (cCRT).